Best Healthcare Stocks Based on a Self-learning Algorithm: Returns up to 24.54% in 14 Days

Best Healthcare Stocks

This Healthcare Stocks Package is designed for investors and analysts who need predictions of the best shares within the Healthcare Sector. It includes 20 stocks with bullish and bearish signals and indicates the best healthcare stocks to buy and sell:

  • Top 10 HealthCare stocks for the long position
  • Top 10 HealthCare stocks for the short position

Healthcare
Package Name: HealthCare Stocks
Recommended Positions: Long
Forecast Length: 14 Days (12/05/2017 – 12/19/2017)
I Know First Average: 7.95%
Best Healthcare Stocks

For this 14 Days forecast the algorithm had successfully predicted 8 out of 10 movements. The highest trade return came from SCMP, at 24.54%. The suggested trades for TEVA and DVA also had notable 14 Days yields of 18.94% and 15.94%, respectively. The overall average return in this HealthCare Stocks package was 7.95%, providing investors with a 6.36% premium over the S&P 500’s return of 1.59% during the same period.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.